Replies to post #24856 on Lifeline Biotechnologies Inc (LLBO)

[rmilman]

Hard to find anything current.

https://www.einpresswire.com/article/389814801/lifeline-biotechnologies-updates

[pearsby09]

This is a copy/paste (Below) of the 12/22/17 link Grove has kindly provided. This is on the MetaScope(TM) not the IT Bra..but still a welcome company development. I still have not located the 12/28/17 news release. Thanks Grove..could you copy/paste the 12/28..TIA

RENO, Nev. -- Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN) today announced that the Company has successfully completed the testing of MastaScope(TM) at three different hospitals in China. The MastaScope(TM) product provides sharp, clear, and accurate imagery of the intraductal breast tissues and abnormalities.

The MastaScope(TM) was tested on 17 patients by Chinese surgeons under the direction of Dr. Pedro Escobar. Dr. Escobar is a Fellow in Breast and Gynecologic Oncology at the Cleveland Clinic Foundation. The surgeons were able to insert the MastaScope(TM), which is a micro-endoscope, through the patient's nipple so the surgeon can examine the interior of the milk duct during the examination. Lifeline Biotechnologies already has been issued the Import Registration Number by the Chinese SDA, which is the equivalent to the American FDA.

"The MastaScope(TM) was very well received by chief breast surgeons at the Zheijang Province People's Hospital, as well as the China-Japan Friendship Hospital and Beijing Third University Hospital. All the scopes and duct excisions were successful," stated Dr. Pedro Escobar.

"The completion of the testing of the MastaScope(TM) will enable us to continue with our strategy in entering the Chinese and Asian markets," stated Jim D. Holmes, CEO of Lifeline Biotechnologies, Inc.

About Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.